ICH Q11 Q&A - A Supporting Document for the Selection and Justification of Starting Materials

Drug Substance Facilities – Hidden and Critical Intermediate

Drug Master File (DMF) Submissions on New FDA Form 3938

OTC Monograph Reform: OTC Sunscreen Drugs

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

ICH Q12 Guidance and Emerging Technology Program (11of16) Generic Drugs Forum 2020

Process Validation and ICH Q7

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA Celebrates 120 Years

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA’s Rare Disease Day 2026 – An Event for Patients

FDA Direct: Combating Rare Diseases at the FDA

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

2025 FDA Achievements